Rare diseases:
collecting best practice and research recommendations

Karen Ritchie, Jenny Harbour, Lorna Thompson
Healthcare Improvement Scotland

"Create a platform to improve the management of rare disease patients"

- Promote communication on rare diseases by disseminating trustworthy guidelines
- Identify rare diseases research needs
- Facilitate timely, effective and efficient translation of research into patient oriented clinical and public health practice

WORK PACKAGE 4: BUILDING COLLECTIONS

- Developing collection criteria: procedures for collection of guidelines and research recommendations
- Collection and evaluation of existing guidelines
- Identifying and collecting recommendations for research
- Horizon scanning to monitor emerging evidence on diseases
- Meta level guideline on evidence translation for RD

WORK PACKAGE 4: BUILDING COLLECTIONS

- Developing collection criteria: procedures for collection of guidelines and research recommendations
- Collection and evaluation of existing guidelines
- Identifying and collecting recommendations for research
- Horizon scanning to monitor emerging evidence on rare diseases
- Meta level guideline on evidence translation for RD

TOOLS AND PROCEDURES



Rare Best Practices

WP4 collection development procedure manual

V2.0Final

Best practice and knowledge sharing in the clinical management of rare diseases

(*RARE-Bestpractices*)

Author(s)

Michele Hilton Boon, Jan Manson, Karen Ritchie



Rare Best Practices

WP4 guidance on searching for guidelines V1.0Final

Best practice and knowledge sharing in the clinical management of rare diseases

(*RARE-Bestpractices*)

Author(s)

Michele Hilton Boon, Jan Manson, Karen Ritchie

	A	B	C
	RARE-Bestpractices		
	Name of searcher		
	Date of searches	13/02/2015	
	Disease/condition	Klinefelter	
	Synonyms	XXY syndrome, XXY trisomy/ies	
	Prevalence	6-9/10,000	
	ICD10	Q98.0, Q98.1, Q98.2, Q98.4	
	OMIN#		
	SNOMed CT		
		Search terms	**Total number of res**
	Orphanet	klinefelter, XXY	
	G-I-N	klinefelter, XXY	
	National Guidelines Clearinghouse	klinefelter, XXY	
	EuroGentest molecular testing		
	EuroGentest clinical utility gene cards		
	NICE Evidence search		
	Google 100	klinefelter, XXY	
	PubMed		
	Patient websites		
	Klinefelter syndrome association UK		

APPRAISAL OF GUIDELINES RESEARCH & EVALUATION

AGREE

National Centre for Rare Diseases CNMR

ISTITUTO SUPERIORE DI SANITÀ

WHICH RARE DISEASES?

- > 6000 recognised rare conditions to choose from!

An initial list of disease topics derived from:

- Search protocol test conditions: purposive sample of high, medium and low prevalence RDs
- Project partner and advisory board areas of interest
- Clinical Knowledge Summaries topic suggestions
- European Academy of Paediatrics (EAP)
- EURORDIS Federation

Addison's disease	Congenital cataract	Hirschsprung's disease	Noonan syndrome
Alstrom disease	Congenital myasthenias	Huntington's disease	Osteosarcoma
Anal atresia	Costello syndrome	Joint hypermobility syndrome	Paroxysmal haemoglobinuria
Aniridia	Cushing's syndrome	Klinefelter's syndrome	Phaeochromocytoma
Bardet Biedl disease	Cushing's disease	Lichen sclerosis	Phenylketonuria
Biliary atresia	Cystic fibrosis	Long QT syndrome	Porphyrias*
Brucellosis (human)	Epidermolysis bullosa	Lyme disease	Progressive subnuclear palsy
Carcinoid syndrome	Gaucher's disease	Mitochondrial disease * (multiple disorder)	Turner syndrome
Catatrophic antiphospholipid syndrome	Giant cell arteritis	Multiple myeloma	Waldenstrom macroglobunemia
Coarctation of the aorta in the newborn	Hereditary spastic paraplegia (Strumpell-Lorrain disease)	Myasthenia gravis	Wolfram disease
Congenital anaemias*	Herpes simplex encephalitis	Neuromuscular disorders* (incl. Duchenne muscular dystrophy & Spinal muscular atrophy)	

Addison's disease	Congenital cataract	Hirschsprung's disease	Noonan syndrome
Alstrom disease	Congenital myasthenias	Huntington's disease	Osteosarcoma
Anal atresia	Costello syndrome	Joint hypermobility syndrome	Paroxysmal haemoglobinuria
Aniridia	Cushing's syndrome	Klinefelter's syndrome	Phaeochromocytoma
Bardet Biedl disease	Cushing's disease	Lichen sclerosis	Phenylketonuria
Biliary atresia	Cystic fibrosis	Long QT syndrome	Porphyrias*
Brucellosis (human)	Epidermolysis bullosa	Lyme disease	Progressive subnuclear palsy
Carcinoid syndrome	Gaucher's disease	Mitochondrial disease * (multiple disorder)	Turner syndrome
Catatrophic antiphospholipid syndrome	Giant cell arteritis	Multiple myeloma	Waldenstrom macroglobunemia
Coarctation of the aorta in the newborn	Hereditary spastic paraplegia (Strumpell-Lorrain disease)	Myasthenia gravis	Wolfram disease
Congenital anaemias*	Herpes simplex encephalitis	Neuromuscular disorders* (incl. Duchenne muscular dystrophy & Spinal muscular atrophy)	

Addison's disease	Congenital cataract	Hirschsprung's disease	Noonan syndrome
Alstrom disease	Congenital myasthenias	Huntington's disease	Osteosarcoma 6
Anal atresia	Costello syndrome	Joint hypermobility syndrome	Paroxysmal haemoglobinuria
Aniridia 1	Cushing's syndrome	Klinefelter's syndrome 2	Phaeochromocytoma
Bardet Biedl disease	Cushing's disease	Lichen sclerosis	Phenylketonuria 1
Biliary atresia	Cystic fibrosis 12	Long QT syndrome	Porphyrias*
Brucellosis (human)	Epidermolysis bullosa 1	Lyme disease 4	Progressive subnuclear palsy
Carcinoid syndrome	Gaucher's disease	Mitochondrial disease * (multiple disorder) 2	Turner syndrome 3
Catatrophic antiphospholipid syndrome 3	Giant cell arteritis	Multiple myeloma 2	Waldenstrom macroglobunemia 3
Coarctation of the aorta in the newborn 2	Hereditary spastic paraplegia (Strumpell-Lorrain disease) 2	Myasthenia gravis 6	Wolfram disease 1
Congenital anaemias* 10	Herpes simplex encephalitis	Neuromuscular disorders* (incl. Duchenne muscular dystrophy & Spinal muscular atrophy) 9	

CONTRIBUTORS (SEARCH & EVALUATION)

Jenny Harbour
Mar Trujillo Martin
Jan Manson
Pierpaolo Mincarone
Maurella Della Seta
Rosaria Rosanna Camaro
Letizia Sampaolo
Antonio Antalia
Merryn Pearce
Avril Kennan
Ali McAllister
Nadia Radulescu
Paula Bray
Melanie Meniar
Lorna Thompson
Carlo Leo
Ingrid Tows

Karen Ritchie
Juliet Brown
Maria Givony
Marco Carnone
Maria Chiara de Stefano
Emelia Severin
Marco Anelli
Sigita Burokiene
Mirella Marino
Marco Crimi
Paola Laricchiuta
Cristina Morciano
Jean Benard

ABOUT RARE-GAP

- Collection of validated research recommendations for diagnosis and treatment of rare diseases

- Research recommendations are statements that describe "*the need for further research, and the nature of the further research that would be most desirable*" (Cochrane Handbook for Systematic Reviews of Interventions, 2011)

- Identified from high quality systematic reviews (Cochrane Library) and presented with information on ongoing clinical trials where available

- Used to prioritise research efforts and resources

C (View Summary Descriptions)

- Congenital toxoplasmosis: prenatal education
- Cystic fibrosis: inhaled antibiotics
- Cystic fibrosis: switching to new nebuliser systems for cystic fibrosis
- Cystic fibrosis: vitamin D supplementation for cystic fibrosis

top

D (View Summary Descriptions)

- Dravet's Syndrome: antiepileptic drugs (stiripentol) for the treatment of severe myoclonic epilepsy in infancy
- Duchenne muscular dystrophy: scoliosis surgery

top

G (View Summary Descriptions)

- Gaucher disease: enzyme replacement and substrate reduction therapy
- Giant cell arteritis: low-dose aspirin
- Guillain-Barre syndrome: pharmacological management of pain

http://rbpresearch.eu/

RECOMMENDATIONS DATABASE

Research Recommendation Summary

Research is required to further explore enzyme replacement and substrate reduction therapies in Gaucher disease.

Evidence Based Recommendation

Evidence (Citations)

Systematic Review	Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database of Systematic Reviews 2015, issue 3. URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010324.pub2/epdf DOI:10.1002/14651858.CD010324.pub2
Other References	Not Applicable
Ongoing Reviews	Not Applicable
Ongoing Studies	A multi-center, open-label, efficacy and safety study of velaglucerase alfa enzyme replacement therapy in children and adolescents with type 3 Gaucher disease. ID: CTRI/2012/05/002666. URL: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/05/002666 A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 (ENGAGE). ID: NCT00891202. URL: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT00891202

RARE-GUIDELINE

- Collection of clinical practice guidelines on rare diseases
- Defined as systematically developed statements which assist providers, patients and stakeholders to make informed decisions about appropriate health care for specific circumstances
- The quality of the methods used to develop each guideline has been evaluated
- Inclusion criteria:
  - Any aspect of care for a rare disease (diagnosis, treatment, etc)
  - Must contain recommendations
  - Published in last 10 years
  - English, French, Spanish, Dutch, Italian, German

B (View Summary Descriptions)

Best practice guidance for the diagnosis and management of cystic fibrosis associated liver disease

Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders: updated European recommendations

Bone cancer

Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

British Thoracic Society guideline for respiratory management of children with neuromuscular weakness

C (View Summary Descriptions)

Care of girls and women with Turner syndrome: a guideline of the Turner syndrome study group

Catastrophic antiphospholipid syndrome: updated diagnostic algorithms

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice

Consensus on timing of intervention for common congenital heart diseases

Consensus statement on diagnosis and clinical management of Klinefelter syndrome

Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis

Cystic Fibrosis Pulmonary Guidelines Chronic Medications for Maintenance of Lung Health

Cystic fibrosis pulmonary guidelines pulmonary complications: hemoptysis and pneumothorax

GUIDELINES DATABASE

Mifamurtide for the treatment of osteosarcoma

Current Version | Status and Details | Guideline Evaluation | Guideline Development | Associated Information | Historic Versions | Print

Hide Navigation

NICE. Mifamurtide for the treatment of osteosarcoma. Technology appraisal 235. 2011 [cited 12 Feb 2016]; Available from: http://www.nice.org.uk/guidance/ta235

You can access the full text of this guideline using the link above. Before you look at the guideline you might want to click on the **"Guideline Evaluation"** link to find out what others thought of the quality of the guideline. Alternatively you can access the guideline and any associated documents we located using the **"Associated Information"** link.

http://rbpguidelines.eu/

Question	Evaluators: 2	
Scope and Purpose	**Response**	**Comments**
1. The overall objective(s) of the guideline is (are) specifically described.	3	No clear objective is specified but the title gives a clear indication of the subject.
	4	None
2. The health question(s) covered by the guideline is (are) specifically described.	2	Limited information on health questions. Mainly consider clinical effectiveness and cost effectiveness of single treatment.
	3	Key Questions are not used in this guidance however, sections are clearly laid out and show the topic they are addressing
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.	5	Detailed description given on age group, condition and treatment status at which mifamurtide to be used.
	4	None
Stakeholder Involvement	**Response**	**Comments**
4. The guideline development group includes individuals from all relevant professional groups.	4	Document is guidance based on assessment of manufacturer submission to a committee which contains a range of specialities.
	1	Not stated and this is a manufacturers submission so unlikely
5. The views and preferences of the target population (patients, public, etc.) have been sought.	5	Patient experts consulted about the submission.
	1	Not stated
6. The target users of the guideline are clearly defined.	4	Target users are not specifically defined, however NICE guidance in mandatory in England.
	3	Not stated, but fairly select clinical groups would use or access this
Rigour of Development	**Response**	**Comments**
7. Systematic methods were used to search for evidence.	1	Not Applicable
	1	Not stated

HOW CAN YOU GET INVOLVED?

- Limited time remaining to expand the collection (Dec 2016)
- More volunteers needed to search for guidelines and appraise guidelines using AGREE II
- If you would like to contribute, contact:

Jenny Harbour
Healthcare Improvement Scotland
jenny.harbour@nhs.net

QUESTIONS/COMMENTS